Gamma camera probe developer Neoprobe of Dublin, OH, said it has enrolled enough clinical subjects to achieve its minimum goal for a multicenter phase III study of its Lymphoseek radiotracer.
The study, which reached its accrual objective of 196 lymph nodes, was conducted in patients with either breast cancer or melanoma. The company stated that full data will be available in the second quarter of 2011 after a clinical review.
To date, no incidents related to drug safety have been reported in the Lymphoseek clinical studies.
